Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OCTRU have now given Green Light approval for The World Hip Trauma Evaluation (WHiTE) Platform and its first embedded randomised comparison WHiTE 11 FRUITI: Fix or Replace Undisplaced Intracapsular fractures Trial of Interventions, which is now open to recruitment. The WHiTE Platform is a clinical trials framework designed to efficiently deliver multiple randomised comparisons of interventions for fragility hip fracture in those aged 60 and over. The FRUITI comparison aims to determine whether there is a difference in health-related quality of life at four months after surgery in patients with undisplaced intracapsular fractures treated with internal fixation or hip replacement.

 Follow on Twitter! @WHiTEPlatform  @WHiTE11FRUITI

 

Similar stories

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.

FUTURE-GB looking ahead to 2022

FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.